QC
ETON icon

Quantessence Capital’s Eton Pharmaceutcials ETON Stock Holding History

Quantessence Capital’s Portfolio ETON Stock Details ETON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,590
Closed -$215K – 268
2025
Q1 		$215K Buy
+16,590
New +$251K 0.05% 272

Other funds holding ETON

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DSCM
Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $653M AUM 28.36% 1-Year Est. Return

Quantessence Capital's ETON Position: Q2 2025 in Review

Quantessence Capital sold out of Eton Pharmaceutcials (ETON) in Q2 2025, closing a stake of 16,590 shares — an estimated $215K sold.

Quantessence Capital first reported a position in ETON in Q1 2025 and held it in 1 quarter. The position peaked at $215K in Q1 2025. 87 funds tracked by Wall St. Rank hold ETON as of Q2 2025.

  • Quantessence Capital reported no remaining Eton Pharmaceutcials position as of Q2 2025 after selling out during the quarter.
  • Quantessence Capital sold 16,590 Eton Pharmaceutcials shares in Q2 2025, an estimated $215K.
  • Quantessence Capital first reported a position in Eton Pharmaceutcials in Q1 2025 and held it in 1 quarter.
  • Quantessence Capital's Eton Pharmaceutcials position peaked at $215K in Q1 2025.
  • 87 funds tracked by Wall St. Rank held Eton Pharmaceutcials as of Q2 2025.

Based on Quantessence Capital's 13F filing for Q2 2025, filed 14 Aug 2025.